← Leaderboards
Henry H Ruiz
New York University School Of Medicine
$722,270
Attributed
$722,270
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $163.4K · FY2020–25$200K$150K$100K$50K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$722,270 · 2
By mechanism
K01$491,797 · 1
R03$230,473 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Katerina Heran Darwin$14,575,170
- Brian Elbel$20,529,886
- Josef Coresh$115,254,828
Others in their field
Other Emerging Leaders on “Obesity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Ted Ross · University Of Georgia$71,962,304
- Barbara Halina Braffett · George Washington University$17,257,975
- Ionut Bebu · George Washington University$14,057,850
- Michael P Harms · Washington University$13,645,932
- Jorge Eduardo Chavarro · Harvard School Of Public Health$13,580,472
Research focus
ObesityThinnessLaboratoriesNew Therapeutic TargetTherapeutic TargetRegulationHuman SubjectKnockout MiceLipidsMediatingPreventOverexpressionBody Weight DecreasedProteinsDiabetes MellitusFutureImpairmentInsulin ResistanceDietLinkLiverCharacteristicsAdipose TissueWild Type Mouse
Grant awards (8)
Zinc Finger Protein 949 as a Potential Transcriptional Suppressor of Adipocyte Hypertrophy - Resubmission - 1$114,750
R03 · FY2025 · DK · contact PI
Zinc Finger Protein 949 as a Potential Transcriptional Suppressor of Adipocyte Hypertrophy - Resubmission - 1$105,723
R03 · FY2024 · DK · contact PI
Zinc Finger Protein 949 as a Potential Transcriptional Suppressor of Adipocyte Hypertrophy - Resubmission - 1$10,000
R03 · FY2024 · DK · contact PI
Advanced Glycation Endproducts, RAGE/DIAPH1 Signaling and Metabolic Dysfunction$108,955
K01 · FY2023 · DK · contact PI
Advanced Glycation Endproducts, RAGE/DIAPH1 Signaling and Metabolic Dysfunction$54,477
K01 · FY2023 · DK · contact PI
Advanced Glycation Endproducts, RAGE/DIAPH1 Signaling and Metabolic Dysfunction$108,955
K01 · FY2022 · DK · contact PI
Advanced Glycation Endproducts, RAGE/DIAPH1 Signaling and Metabolic Dysfunction$108,955
K01 · FY2021 · DK · contact PI
Advanced Glycation Endproducts, RAGE/DIAPH1 Signaling and Metabolic Dysfunction$110,455
K01 · FY2020 · DK · contact PI